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The bone disease in multiple myeloma is
caused by an uncoupling of bone forma-
tion from bone resorption. A key differ-
ence between patients with and patients
without osteolytic lesion is that the latter
have fewer and less active osteoblasts.
Hepatocyte growth factor (HGF) is often
produced by myeloma cells and is found
at high concentrations in the bone mar-
row of patients with multiple myeloma.
Here we show that HGF inhibited bone
morphogenetic protein (BMP)–induced in
vitro osteoblastogenesis. Thus, HGF in-
hibited BMP-induced expression of alka-
line phosphatase in human mesenchymal
stem cells (hMSCs) and the murine myoid
cell line C2C12, as well as mineralization
by hMSCs. Furthermore, the expression
of the osteoblast-specific transcription
factors Runx2 and Osterix was reduced
by HGF treatment. HGF promoted prolif-
eration of hMSCs, and the BMP-induced
halt in proliferation was overridden by
HGF, keeping the cells in a proliferative,
undifferentiating state. BMP-induced
nuclear translocation of receptor-activated
Smads was inhibited by HGF, providing a
possible explanation of how HGF inhibits
BMP signaling. The in vitro data were
supported by the observation of a nega-
tive correlation between HGF and a marker
of osteoblast activity, bone-specific alka-
line phosphatase (rho  0.45, P  .008),
in sera from 34 patients with myeloma.
These observations suggest that HGF
inhibits bone formation in multiple my-
eloma. (Blood. 2007;109:3024-3030)
© 2007 by The American Society of Hematology
Introduction
Almost all patients with multiple myeloma develop osteolytic
lesions and/or diffuse osteopenia. The presence of myeloma
cells in the bone marrow leads to both increased number and
activity of osteoclasts as well as reduced number and dysfunc-
tion of osteoblasts.1,2 During the early stages of the disease,
enhanced osteoclast activation is at least partly compensated by
an increase in bone formation. As the disease progresses, the
osteoblasts are fewer and less active, so that bone resorption is
uncoupled from bone formation.3 Recently, several factors have
been proposed to be involved in the dysregulation of osteoblas-
togenesis in multiple myeloma.4-7 However, the mechanisms for
reduced bone formation in patients with myeloma are still not
completely understood.
We have shown that myeloma cells produce hepatocyte growth
factor (HGF).8 Others have shown that HGF is among the most
upregulated genes in myeloma cells as compared with normal
plasma cells.9 High serum concentration of HGF is associated with
poor prognosis in patients with myeloma,10 and HGF has been
shown to play several roles in disease progression.11-16 Further-
more, we have shown that HGF is found at high concentrations in
bone marrow plasma from patients with myeloma.17
In a mouse model of multiple myeloma developed in our
laboratory, a prominent feature was the complete lack of osteo-
blasts.18 In this model, JJN3 cells, which produce high levels of
HGF, were injected into severe combined immunodeficient (SCID)
mice. The concentration of HGF in the bone marrow plasma of
the mice was high; in some mice the concentration exceeded
5 g/mL.18 We therefore hypothesized that HGF can interfere with
osteoblastogenesis, and thereby be a factor responsible for the
reduced number and reduced activity of osteoblasts in patients with
multiple myeloma.
Materials and methods
Cells and cell culture conditions
C2C12 cells (ATTC, Rockville, MD) were routinely maintained in Dul-
becco modified Eagle medium (DMEM; Gibco, Carlsbad, CA) with 15%
heat inactivated fetal calf serum (FCS; EuroClone, Pero, Italy) in a
humidified atmosphere containing 5% CO2 at 37°C. Cells were not allowed
to reach confluence, and were used before they completed 8 passages.
Human mesenchymal stem cells (hMSCs) were purchased from Cambrex
Bio Science and routinely maintained in human mesenchymal stem cells
growth media (MSCGM; Cambrex Bio Science, East Rutherford, NJ)
according to the manufacturer’s instructions. hMSCs were used before they
completed 8 passages.
Osteoblast differentiation
hMSCs were seeded at 4000 cells/cm2 and cultured until they reached 70%
confluence. Then, osteogenic differentiation was induced by adding dexa-
methasone (108 M; Sigma-Aldrich, St Louis, MO), beta-glycerophosphate
(10 mM; Sigma-Aldrich), and L-ascorbic acid (0.05 mM; Sigma-Aldrich)
with or without BMP-2 (300 ng/mL; R&D Systems, Minneapolis, MN) and
HGF (100 ng/mL; R&D Systems). Media were renewed every 3 to 4 days.
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C2C12 cells were seeded at 10 000 cells/cm2 in DMEM/1% FCS with or
without BMP-2 (300 ng/mL) and HGF (100 ng/mL).
ALP assay
Alkaline phosphatase (ALP) activity was quantified by ELF 97 Endogenous
Phosphatase Detection Kit (Molecular Probes, Eugene, OR). Briefly, cells
in 96-well plates were fixed in 3% para-formaldehyde for 10 minutes at
room temperature. To permeabilize the cells, 200 L/well of phosphate-
buffered saline (PBS)/0.2% Tween-20 was added and the plates were
incubated for 15 minutes. The cells were briefly rinsed twice in water, and
then left for 10 minutes in H2O. Substrate was diluted 1:20 in substrate
buffer, 50 L/well, and incubated for 5 minutes. Then, fluorescence was
detected using a multilabel counter (Viktor 1420; Perkin Elmer, Wellesley,
MA) with excitation filter at 355 nm and emission filter at 535 nm. To adjust
for differences in cell number, cells were subsequently lysed in either 100
L 10% SDS or 150 L 1X SSC/100 g/mL proteinase K, and total protein
(Micro BCA protein assay kit; Pierce, Rockford, IL) or DNA (SybrGreen),
respectively, were measured. In parallel, to visualize ALP expression, cells
were stained with the Leukocyte Alkaline Phosphatase Kit (Sigma-Aldrich)
according to the manufacturer’s instruction.
Mineralization
hMSCs were seeded in 24-well plates and cultured for 14 and 17 days.
Media were renewed every 3 to 4 days. Cultures were terminated by fixing
cells in 3% para-formaldehyde for 10 minutes on ice. Fixed cultures were
rinsed with PBS and then with water, thereafter stained with 500 L/well 40
mM Alizarin Red-S (ARS; Sigma-Aldrich) at pH 4.2 and room temperature
with gentle agitation. Cells were then washed 5 times with water followed
by a 15-minute rinse with PBS under gentle rotation. Stained cultures
were photographed, then destained by incubating in 10% (wt/vol)
cetylpyridinium chloride (CPC) in 10 mM sodium phosphate buffer pH
7.0 for 1 hour at room temperature. ARS concentration in these extracts was
determined by absorbance at 562 nm. A standard curve was obtained by
diluting ARS in CPC.
Real-time RT-PCR
Total RNA was isolated using the High Pure RNA Isolation Kit (Roche
Applied Science, Indianapolis, IN). A Transcriptor First Strand cDNA
Synthesis kit (Roche Applied Science) was used to synthesize cDNA using
oligo dT-primers according to the manufacturer’s instructions. RNA (2 g)
was used as a template in the cDNA synthesis reaction. PCR was carried out
with the LC Fast Start DNA Master SYBR Green kit (Roche Applied
Science) using 2.0 L cDNA, corresponding to 20 ng total RNA in 20 L
final volume with 4 mM MgCl2 and 0.5 M of each primer. Relative
quantitative PCR was performed using LightCycler (Roche Applied
Science). Briefly, after an initial step of denaturation at 95°C for 20 seconds,
45 cycles of amplification were run containing the following steps: 95°C for
10 seconds, specific annealing temperature for 5 seconds, and extension at
72°C for the number of seconds as determined by the formula: product
size/25. Amplification specificity was checked using melting curve analy-
sis. Primers and annealing temperatures were as follows: RUNX2, forward
5-CCAAGAAGGCACAGACAGAAGC-3 and reverse 5-CTGCCTG-
GCTCTTCTTACTGAG-3, annealing temperature 68°C, extension time
17 seconds; Osterix, forward 5-ATGGCGTCCTCTCTGCTTGA-3 and
reverse 5-GGGAGCAAAGTCAGATGGGTAA-3, annealing temperature
64°C, extension time 27 seconds; GAPDH, forward 5-CACCATG-
GAGAAGGC-3 and reverse 5-GACGGACACATTGGGGGTAG-3. Re-
sults were analyzed with LightCycler Software v.3.5 (Roche Applied
Science) using the second derivative maximum method to set crossing
points. The crossing points obtained are a function of the amplification
efficiency of the respective PCR. To adjust for differences in PCR
efficiency, relative standard curves were obtained from 5-fold dilutions of
pooled cDNA (corresponding to 40 ng RNA to 32 pg RNA) from
BMP-2–treated C2C12 cells for both target and reference genes. Then,
calibrator-normalized relative quantification with efficiency correction was
carried out with Real Quant Software (Roche Applied Science). Samples
were run in triplicate. The ratio of target mRNA to GAPDH in control
samples was set to 1.
Western blot
Nuclear extracts were prepared using the Nuclear Extract Kit (Active Motif,
Rixensart, Belgium) according to the manufacturer’s instructions. Protein
(30-100 g) was loaded onto precasted 10% to 12% Bis-Tris Gels
(Invitrogen, Carlsbad, CA) and subjected to SDS–polyacrylamide gel
electrophoresis (PAGE). Gels were then blotted onto nitrocellulose mem-
branes. Membranes were blocked in 5% nonfat dry milk in 0.1%
Tween-20–Tris buffered saline pH 7.4 (TBST) for 1 hour at room
temperature. Anti-Runx2 (clone 8G5; MBL International, Woburn, MA, or
R&D Systems), anti–phospho–Smads 1, 5, and 8 (Cell Signaling, Danvers,
MA), anti-PCNA (Santa Cruz Biotechnology, Santa Cruz, CA), and
anti-GAPDH (AbCam) were incubated overnight at 4°C in 5% nonfat dry
milk in TBST. Membranes were washed 4 times and incubated with an
appropriate secondary antibody for 1 hour at room temperature. Following
4 washes in TBST the membranes were developed with enhanced chemilu-
minescence detection reagents (ECL; Amersham Biosciences, Amersham,
United Kingdom) according to manufacturer’s instructions and exposed to
Hyperfilm ECL (Amersham Bisociences).
Proliferation
To measure DNA synthesis, hMSCs were seeded in 96-well plates at a
density of 5000 cells/well in 200 L MSCGM supplemented with
dexamethasone (108 M), beta-glycerophosphate, L-ascorbic acid (0.05
mM), and cytokines as indicated for each experiment. After 1, 2, or 7 days,
the cells were pulsed with 0.75 Ci (27/750 Bq) methyl-3H-thymidine
(NEN Life Science Products, Boston, MA) per well and harvested 18 hours
later with a Micromate 96-well harvester (Packard, Meriden, CT). Beta
radiation was measured with a Matrix 96 counter (Packard).
Immunofluorescence microscopy
C2C12 cells were serum starved for 24 hours before treatment with BMP-2
(300 ng/mL) and/or HGF (100 ng/mL) for 45 minutes. Then the cells were
fixed on ice with 3% para-formaldehyde in PBS for 10 minutes. Subse-
quently, the cells were blocked and permeabilized with 2.5% BSA/20%
Aserum/0.2% saponin in PBS (blocking/permeabilization buffer) for 20
minutes. Anti–phospho–Smads 1, 5, and 8 (Cell Signaling) were diluted
1:100 in blocking buffer and incubated for 1 hour. After 3 washes in
blocking buffer, Alexa-633–conjugated goat antirabbit (Molecular Probes)
was added and cells were incubated for 45 minutes. The cells were
subsequently washed twice before examination. Images were acquired and
viewed using an Axiovert 100M microscope equipped with a Zeiss
LSM510 Meta scanning unit and a 63/1.4 numerical aperture oil
immersion objective (all from Zeiss, Jena, Germany). Captured images
were processed using Zeiss LSM510 software and Adobe Photoshop
(Adobe Systems, San Jose, CA). Unless otherwise stated, the procedure was
performed at room temperature. Cells that had fluorescence intensity in the
nucleus higher than a certain threshold (100 pixels) were counted as
positive for phospho–Smad 1, 5, and 8 nuclear translocation.
Transfection and reporter assay
hMSCs (500 000) were transfected with 2.0 g of the BMP-responsive
luciferase reporter construct BRE-Luc19 (kindly provided by Dr O.
Korchynskyi and Prof Peter ten Dijke) using a human MSC Nucleofector
Kit (Amaxa Biosystems, Cologne, Germany) and program C-17 on the
Amaxa Nucleofector (Amaxa Biosystems). The cells were then seeded in
96-well plates, 30 000 cells/well in MSCGM, and cultured overnight. The
next day, cells were stimulated for 5 hours in MSCGM with or without
BMP-2 (300 ng/mL) or HGF (100 ng/mL). Then media were removed, the
cells washed with PBS, and 20 L 1X cell culture lysis reagent (Promega,
Madison, WI) were added to lyse the cells. Luciferase assay substrate (70
L; Promega) were added to 15 L of the lysates, and luciferase activity
was measured using a luminometer (Viktor 1420; Perkin Elmer). By
transfecting hMSCs with pMaxGFP (Amaxa Biosystems) the transfection
efficiency was determined to be 40% to 50%.
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Patients
Sera from 34 patients with newly diagnosed multiple myeloma were
analyzed in the in vivo part of the study. All patients had symptomatic
disease and an expected distribution of myeloma subtypes: 25 patients had
IgG subtype, 5 patients IgA, 3 patients light chain disease, and 1 patient
nonsecretory disease. All but 2 patients had lytic bone disease and/or
pathologic fractures. Sera were taken before start of treatment and stored at
80°C until analysis. The study was approved by the local ethics
committee at Aarhus University Hospital. Informed consent was provided
according to the Declaration of Helsinki. Patient characteristics have been
described in detail elsewhere.20
Serum assays
HGF in serum was measured by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions (R&D Systems).
Markers of bone formation. Total alkaline phosphatase activity in
serum was measured spectrophotometrically using p-nitrophenylphosphate
as a substrate, and the bone-specific alkaline phosphatase (bALP) was
determined by lectin precipitation.21 The N-terminal propeptide (PINP) and
the C-terminal propeptide (PICP) of procollagen type I were measured by
radioimmunoassay (RIA) from Farmos Diagnostica (Oulunsalo, Fin-
land).22,23 Osteocalcin (OCN) in serum was determined by RIA.24
Markers of bone resorption. Serum concentration of C-terminal
telopeptide of collagen type I (ICTP) was analyzed by 2 different assays, the
ICTP RIA assay from Farmos Diagnostica, which uses rabbit polyclonal
antibodies for detection of a cross-linked fragment liberated by metallopro-
teinase activity,25,26 and the Ctx-1 -Crosslaps electrochemoluminescence
immunoassay from Roche Diagnostics (Mannheim, Germany), which uses
2 monoclonal murine antibodies recognizing -8AA octapeptides within
telopeptide fragments liberated by cathepsin K.27,28 The N-terminal telopep-
tide of collagen type I (Ntx-1) in urine was measured by an ELISA
inhibition assay from Ostex (Seattle, WA).29 Ntx-1 results were expressed
as nmol bone collagen equivalent per mmol creatinine.
Statistics
Statistical analyses were performed with the SPSSX/PC computer program
(SPSS, Chicago, IL). Results were considered statistically significant when
P  .05. Skewed variables (Kurtosis  7) were transformed by the natural
logarithm (ln) before entering analyses requiring normal distribution.
Results
HGF inhibits osteoblast differentiation in vitro
We investigated the role of HGF in BMP-induced osteoblastogen-
esis using 2 different in vitro model systems. C2C12 cells are
murine myoid cells that differentiate to osteoblasts when they are
treated with BMP-2.30 Likewise, when hMSCs are cultured in
osteogenic media (see “Materials and methods”) osteoblast differ-
entiation is induced, and the differentiation is enhanced when the
cells are treated with BMP-2. ALP is frequently used as a marker
for early osteoblast differentiation, whereas osteocalcin and the
accumulation of calcium are used as markers for terminally
differentiated osteoblasts.31 ALP activity of both C2C12 cells
(Figure 1A) and hMSCs (Figure 1B-C) was inhibited by the
addition of HGF. Furthermore, BMP-2 induced osteocalcin expres-
sion of C2C12 cells (Figure 2A), and mineralization of osteoblasts
derived from hMSCs (Figure 2B-C) was inhibited by HGF. Thus,
HGF inhibited both early and late stages of BMP-induced osteo-
blast differentiation.
HGF inhibits the expression of osteoblast-specific
transcription factors Runx2 and Osterix
Osteoblast differentiation is regulated by sequential expression of
the osteoblast-specific transcription factors Runx2 and Osterix.32-35
In C2C12 cells, RUNX2 mRNA was expressed at high levels after 4
days of BMP-2 treatment, and although still present, the expression
decreased after another 2 days of culturing (Figure 3A). Osterix, on
the other hand, was induced later in the differentiation process and
showed high expression after 6 days of BMP-2 treatment (Figure
3B). HGF inhibited the BMP-2–induced expression of both
RUNX2 and Osterix mRNA (Figure 3A-B). The decrease of
BMP-2–induced RUNX2 mRNA in C2C12 cells in the presence of
HGF resulted in a decrease of Runx2 protein expression as shown
in Figure 3C. hMSCs cultured in osteogenic media showed a
basal Runx2 protein expression (Figure 3D). BMP-2 treatment
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Figure 1. HGF inhibits BMP-2–induced
ALP activity in vitro. ALP activity of C2C12
cells (A) and hMSCs (B-C). The hMSCs in (C)
had been treated with cytokines for six days.
The concentrations of cytokines were 300
ng/mL BMP-2 and 100 ng/mL HGF. Data are
presented as means SEM.
Figure 2. HGF inhibits BMP-2–induced terminal differ-
entiation of osteoblasts. Osteocalcin concentration (A)
in conditioned media from C2C12 cells cultured for 6
days. Mineralization of MSCs treated for the indicated
time periods was quantified (B) or visualized (C) by
Alizarin Red-S (ARS) staining. The concentrations of
cytokines were 300 ng/mL BMP-2 and 100 ng/mL HGF.
ND indicates not detected.
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enhanced this basal expression, and more importantly, HGF
inhibited the BMP-induced Runx2 protein expression also in
hMSCs (Figure 3D). In conclusion, HGF inhibits the BMP-2–
induced expression of the osteoblast-specific transcription fac-
tors Runx2 and Osterix.
HGF promotes proliferation of human mesenchymal stem cells
When mesenchymal stem cells differentiate, proliferation is inhib-
ited.31 In line with this, we found that BMP-2 inhibited the
proliferation of hMSCs (Figure 4). Moreover, although HGF alone
had no effect on the expression of osteoblast markers (Figures 1
and 2), we found that HGF treatment promoted proliferation of
hMSCs as compared with both untreated and BMP-2–stimulated
cells (Figure 4). Furthermore, HGF abolished the antiproliferative
effect of BMP-2 (Figure 4), indicating that HGF keeps the cells in a
proliferative, undifferentiated state. The influence on proliferation
was most pronounced during the first 2 days after osteogenic
induction; after 7 days, there was no significant difference in
proliferation rates (data not shown). In contrast, neither BMP-2 nor
HGF had any significant influence on proliferation of C2C12 cells
(data not shown).
HGF inhibits BMP-2 signaling
The osteogenic activity of BMPs is partly mediated by nuclear
translocation of Smads,36 so we wanted to investigate whether
HGF acts on osteoblastogenesis by interfering with Smad
signaling. By confocal microscopy, we looked at the presence of
Smads 1, 5, and 8 in the nucleus of C2C12 cells treated with
BMP-2 and/or HGF. As shown in Figure 5A, HGF treatment
reduced the nuclear translocation of Smads 1, 5, and 8. In 57%
of the cells treated with BMP-2, Smads 1, 5, and 8 were present
in the nucleus, whereas in cells treated with both HGF and
BMP-2 the presence of Smads 1, 5, and 8 was detected in only
21% of the nuclei, which was similar to the level in untreated
cells (Figure 5A). We also performed Western blots of nuclear
extracts of C2C12 cells and found a strong BMP-2–induced
nuclear localization of Smads 1, 5, and 8. The BMP-2–induced
nuclear translocation of Smads 1, 5, and 8 was reduced in the
presence of HGF (Figure 5B). To investigate the effect of HGF
on Smad signaling in hMSCs, we employed a Smad-driven
BMP-reporter construct. As shown in Figure 5C, HGF inhibited
Smad signaling in hMSCs, suggesting that HGF interferes with
immediate BMP signaling also in hMSCs.
The inhibitory effect of conditioned media from myeloma cells
on BMP-2–induced osteoblastogenesis is abolished by
inhibiting HGF signaling
It is shown that patients with myeloma have elevated levels of HGF
in the bone marrow.17 To further verify that HGF derived from
myeloma cells is involved in osteoblast inhibition we tested
whether blocking of HGF signaling in hMSCs would abolish the
inhibitory effect of conditioned media from the HGF-producing
myeloma cell line JJN3. Although a 1:10 dilution of JJN3-
conditioned media slightly increased the basal ALP activity of
hMSCs, the BMP-2–induced ALP activity was inhibited (Figure 6).
A small molecule ATP-competitive inhibitor of c-Met tyrosine
kinase (PHA665 752)37 almost completely reversed the inhibition
of osteoblast differentiation, indicating that at least part of the
inhibitory action of JJN3 supernatant on BMP-induced hMSC
differentiation is due to the presence of HGF.
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Figure 5. HGF inhibits Smad signaling. (A) Detection of phosphorylated (P)–Smad
1, 5, and 8 in C2C12 cells treated for 45 minutes with BMP-2 (300 ng/mL) and/or HGF
(100 ng/mL). (i) Control cells (P–Smad 1, 5, or 8 detected in 19% of the nuclei);
(ii) BMP-2–treated cells (P–Smad 1, 5, or 8 detected in 57% of the nuclei);
(iii) HGF-treated cells (P–Smad 1, 5, or 8 detected in 33 % of the nuclei); and
(iv) BMP-2– and HGF-treated cells (P–Smad 1, 5, or 8 detected in 21% of the
nuclei). (B) Detection of P–Smad 1, 5, and 8 by Western blotting of nuclear extracts of
C2C12 cells treated for 45 minutes as indicated. (C) Luciferase activity of hMSCs
transfected with BRE-luc stimulated for 5 hours as indicated. The concentrations of
cytokines in (A-C) were 300 ng/mL BMP-2 and 100 ng/mL HGF.
Figure 3. HGF inhibits the BMP-2–induced expression of osteoblast-specific
transcription factors. Relative mRNA levels of Runx2 (A) and Osterix (B) in C2C12
cells. Runx2 protein expression detected by Western blotting of nuclear extracts from
C2C12 cells (C) and hMSCs (D) treated for 6 days. The concentrations of cytokines
were 300 ng/mL BMP-2 and 100 ng/mL HGF.
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Figure 4. HGF promotes proliferation of MSCs. MSCs were treated for 1 or 2 days
as indicated before 3H-thymidine was added to the media. The amount of incorpo-
rated 3H-thymdine was measured after another 18 hours of culturing. Bars represent
mean  SEM of triplicate wells. Control levels of 3H-thymidine incorporation per well
were 3866 counts/min on day 1 and 2969 counts/min on day 2. The concentrations of
cytokines were 300 ng/mL BMP-2 and 100 ng/mL HGF.
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HGF correlates negatively with markers of osteoblast activity
in patients with multiple myeloma
Since we found that HGF inhibited osteoblastogenesis in vitro, we
wanted to investigate whether serum concentrations of HGF
correlate with markers of osteoblast activity in patients with
myeloma. We found that HGF correlated significantly to bone-
specific alkaline phosphatase (bALP) in a Spearman rank correla-
tion analysis (r 	 0.45, P 	 .008; Table 1 and Figure S1,
available on the Blood website; see the Supplemental Figure link at
the top of the online article). Serum bALP is a specific marker of
bone formation rate in patients with multiple myeloma,38 so the
finding of a negative correlation between bALP and HGF supports
our in vitro data of HGF as an inhibitor of osteoblastogenesis.
When we logarithmically transformed skewed variables before
entering a Pearson correlation analysis, PINP (r 	 0.374,
P 	 .029) came out in addition to bALP (r 	 0.516, P 	 .002) as
negatively correlated to HGF. PINP is another marker for osteo-
blast activity. Taken together, this strengthens our hypothesis of
HGF as an osteoblast-inhibiting factor in multiple myeloma.
Discussion
BMP signaling has been shown to be essential to obtain osteoblasts
in adult animals.39-41 In this report, we show that HGF inhibits
BMP-2–induced osteoblastogenesis in vitro. The expression of
both early and late markers of osteoblastogenesis was inhibited by
HGF treatment, including the osteoblast-specific transcription
factors Runx2 and Osterix. Furthermore, in patients with myeloma,
serum concentrations of HGF were negatively correlated to mark-
ers of osteoblast activity.
HGF is on the top 10 list of genes that distinguishes myeloma
from Waldenstro¨m macroglobulinemia and chronic lymphocytic
leukemia,42 both B-cell malignancies with some similarity to
myeloma, but with little or no bone affection. On the same list,
members of the Wnt-family Dickkopf-1 (Dkk1) and Frizzled-
related protein are found. These known inhibitors of Wnt signaling
have previously been suggested to be involved in osteoblast
dysfunction in patients with myeloma.4,5 Wnt signaling is impor-
tant for normal skeletogenesis43 and synergizes with BMP to
promote osteoblast differentiation.44,45 Thus, the myeloma cell may
produce factors that inhibit both BMP signaling (HGF) and Wnt
signaling (Dkk1 and sFRP2) pathways. Other factors reported to
inhibit osteoblastogenesis in multiple myeloma are IL-77 and IL-3.6
In contrast to HGF, IL-7 did not inhibit the expression of Runx2,
although the transactivity of Runx2 was reduced.7 IL-3 has been
shown not to act directly on osteoblasts, but indirectly via CD45
cells by an unknown mechanism.6
We found that serum concentration of HGF in patients with
myeloma correlated negatively with bALP. bALP is derived from
osteoblast membranes and is a specific marker of osteoblast
activity in patients with myeloma, correlating well with histomor-
phometrically estimated dynamic indices of bone formation.38
HGF also correlated inversely with PINP, another marker of bone
formation that reflects osteoblastic synthesis of collagen type I.
Alexandrakis et al46 found that HGF was negatively correlated to
osteocalcin, and, although not significant, there was an inverse
association of osteocalcin and HGF in our patient material as well.
However, osteocalcin in the circulation may be both newly
synthesized and released during resorption, so there is some
question as to whether it should be considered a marker for
osteoblast activity.47 In addition, osteocalcin reflects relative os-
teoid surfaces and osteoid thickness more than dynamic indices of
bone formation.38 In a few clinical studies serum concentrations of
HGF have been correlated to markers of osteoclast activity,10,46,48
and recent data suggest that HGF may also directly stimulate
osteoclastogenesis.49 We did not find any significant correlations of
HGF to osteoclast markers in our analyses. However, the number of
patient samples available in this study was relatively small, which
may explain our inability to find the significant correlations
reported earlier.
Osteoblast differentiation is regulated by sequential expression
of the osteoblast-specific transcription factors Runx2 and Os-
terix.32-35 In line with previous studies,50-52 we show that BMP-2
increases expression of Runx2, both in C2C12 cells as well as in
hMSCs. HGF inhibits the BMP-2–induced expression of Runx2,
but does not seem to inhibit the basal level of Runx2 present in
hMSCs cultured in osteogenic media. Similarly, HGF inhibited
BMP-2–induced ALP activity and mineralization, but not the basal
ALP activity and mineralization present in hMSCs cultured in
osteogenic media. However, it should be noted that in some
experiments we observed an inhibition of the basal level of
mineralization upon HGF treatment, but the reduction was nonsignifi-
cant, and might be due to the inhibition of autocrine BMP signaling.53
HGF therefore seemed to specifically target BMP signaling pathways.
BMPs signal through activation of transmembrane serine/
threonine kinase receptors. Ligand binding induces transphospho-
rylation of the type I receptor by the type II receptor kinase. The
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Figure 6. A c-met inhibitor (PHA665752) blunts the inhibitory effect of condi-
tioned media from JJN cells on BMP-2–induced osteoblastogenesis. ALP
activity of hMSCs treated with PHA665752 (100 nM), conditioned media from JJN3
cells diluted 1:10, and BMP-2 (300 ng/mL) for 4 days as indicated. Differences in ALP
activity were statistically significant (independent samples, 2-tailed t test) in untreated
cells versus cells treated with JJN3 Sup (P 	 .007), in untreated cells versus
BMP-2–treated cells (P 	 .001), in BMP-2–treated cells versus cells treated with
BMP-2/JJN-3 Sup (P 	 .008), and in BMP-2/JJN-3 Sup–treated cells versus cells
treated with BMP-2/JJN-3 Sup/PHA665752.
Table 1. Correlations between HGF and markers of bone resorption and bone formation in patients with myeloma, at diagnosis
ICTP Ctx-1 Ntx-1 PINP PICP OCN bALP
Spearman rho 0.214 0.037 0.171 0.316 0.117 0.149 0.449*
Significance (2-tailed) .159 .835 .333 .068 .443 .399 .008
N 45 34 34 34 45 34 34
*Correlation is significant at the .01 level (2-tailed).
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activated type I receptor then phosphorylates receptor Smads
(R-Smads) at specific C-terminal serines. Together with Smad 4,
the phosphorylated R-Smads translocate to the nucleus where they
associate with other proteins to regulate transcription.36 We found
that HGF inhibited Smad signaling both in hMSCs and C2C12
cells, suggesting that the effect of HGF on BMP-induced osteoblas-
togenesis may be due to inhibition of important early steps in the
BMP signaling pathway. Growth factors, including HGF, bind
receptor tyrosine kinases that may activate the Ras-ERK pathway.54
ERK has been shown to directly phosphorylate R-Smads at the
linker region. This phosphorylation inhibits, by unknown mecha-
nisms, the translocation of R-Smads to the nucleus both in vitro and
in vivo,55,56 and provides a possible explanation of how HGF
inhibits Smad signaling. However, non-Smad pathways are also
involved in BMP-induced osteoblast differentiation.57,58 Furthermore, it
has been shown that a Smad-independent RTK-Ras-ERK pathway
inhibits BMP signaling.59 Therefore, at this point we cannot
exclude the possibility that HGF acts on other pathways in addition
to the Smad pathway in the regulation of osteoblast differentiation.
The influence of growth factors on osteoblast differentiation is
reported in several papers, although different mechanisms and even
opposing effects of the same factors have been described.60-66 It
may be that transient exposure to mitotic growth factors such as
FGF, EGF, and PDGF enhance osteogenesis, whereas continuous
exposure inhibits osteoblast differentiation. The enhanced osteogen-
esis could be due to an increased self-renewal of mesenchymal
stem cells that leads to an increase in the number of cells that can
become fully mature osteoblasts when osteogenic stimuli are
present. HGF has been shown by others to stimulate the expression
of early osteoblast markers (ALP activity) in preosteoblasts,67 and
has also been reported to stimulate 1,25-dihydroxyvitamin D3–
induced osteoblast differentiation by increased proliferation of
osteoblast precursors.68 In line with the latter study, we observed a
proliferative effect of HGF on hMSCs. However, in contrast, HGF
on its own had no effect on the differentiation toward osteoblasts,
and, importantly, inhibited BMP-2–induced osteoblastogenesis.
We propose that HGF may act on osteoblastogenesis in 2 different
ways: by promoting self-renewal of hMSCs (possibly at the
sacrifice of differentiation), and by interfering with BMP signaling,
thus directly inhibiting BMP-induced osteoblastogenesis. In the
bone marrow of patients with myeloma, the myeloma cells could
be a source of continuous production of HGF. Supporting this is the
finding that myeloma cell–derived HGF has the same activity as
recombinant HGF.
HGF is found at high concentrations in the bone marrow of
patients with myeloma. We have previously shown that about 50%
of the patients with multiple myeloma have elevated levels of HGF
in bone marrow plasma when compared with healthy persons. In
some of the patients the concentration of HGF in bone marrow
plasma was extremely high, exceeding 100 ng/mL.17 The differen-
tiation of mesenchymal stem cells and osteoblast precursors in
many patients with myeloma thus occurs in an environment
containing abnormal levels of this cytokine. The in vitro and in
vivo data presented in this study suggest that HGF reduces bone
formation rates in patients with myeloma and hereby may contrib-
ute to the development of myeloma bone disease. Consequently,
inhibition of HGF signaling could be useful in the treatment of the
bone disease in multiple myeloma.
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